

LY3200882

Catalog No: tcsc0023129



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1898283-02-7

Formula:

$C_{24}H_{29}N_5O_3$

Pathway:

TGF-beta/Smad

Target:

TGF- β Receptor

Purity / Grade:

>98%

Solubility:

DMSO : 130 mg/mL (298.49 mM; Need ultrasonic and warming)

Observed Molecular Weight:

435.52


Product Description

LY3200882 is a novel and highly selective inhibitor of **TGF- β receptor type 1 (TGF β RI)**.

IC50 & Target: TGFβRI^[1]

In Vitro: LY3200882 is a novel, highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation *in vitro* in tumor and immune cells. LY3200882 has shown anti-metastatic activity *in vitro* in migration assays. In *in vitro* immune suppression assays, LY3200882 has shown the ability to rescue TGFβ1 suppressed or T regulatory cell suppressed naïve T cell activity and restore proliferation^[1].

In Vivo: LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation *in vivo* in subcutaneous tumors in a dose dependent fashion. LY3200882 has shown anti-metastatic activity *in vivo* in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer)^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!